Stock Price Quote

EMERGY PHAARMA LTD.

NSE : NABSE : 524812ISIN CODE : INE586C01016Industry : Pharmaceuticals & DrugsHouse : Private
BSE1.220 (0 %)
PREV CLOSE ( ) 1.22
OPEN PRICE ( ) 1.25
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 0
TODAY'S LOW / HIGH ( )1.25 1.25
52 WK LOW / HIGH ( ) 00
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1993
Management Info
- Chairman - Managing Director
Registered Office

Address 115, Brig Sayeed Road, Hanumanji Colony Tarbund,
Secunderabad,
Andhra Pradesh-500009

Phone 040- 7755235 7756327

Email --

Website NA

Registrars Details
Venture Capital & Corporate Investments Ltd
6-2-913 / 914 , 3rd Floor,Progressive Towers,Khairatabad,Hyderabad
Listing : BSE

NEWS

No News Found

Financials

in Millions
QTR Jun 06 ANNUAL
Net Profit-0.29
Gross Profit -0.29
Operating Profit -0.29
Net Sales

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26946.00 (0.74%)
M.Cap ( in Cr)57258.37
Sanofi India (BSE)
peergroup  8118.25 (2.06%)
M.Cap ( in Cr)18696.83
Dr. Reddy's Lab (BSE)
peergroup  6155.15 (1.78%)
M.Cap ( in Cr)102679.14
Divi's Lab (BSE)
peergroup  3436.75 (2.14%)
M.Cap ( in Cr)91234.91
Glaxosmithkline Phar (BSE)
peergroup  1943.10 (3.26%)
M.Cap ( in Cr)32917.29

Shareholding Pattern

No Data Found

About

no data found

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.